Bayer HealthCare strengthens position in Russia
Bayer enters strategic partnership to locally produce pharmaceuticals in Russia / Partnership will increase access of Russian patients to Bayer medicines
Moscow, November 2, 2012 – Bayer HealthCare and Russian drug manufacturer Medsintez have entered into a strategic partnership to jointly manufacture and commercialize diagnostic imaging products as well as pharmaceuticals to treat infections and neural disorders. In addition, the companies intend to cooperate in the research, development and production of new substances and medicines, aiming to accelerate the access to innovative pharmaceuticals for Russian patients. Joint marketing activities are scheduled to start in 2013.
"The local production of our products will provide additional momentum to our business development in this growth market," said Andreas Fibig, President of Bayer HealthCare Pharmaceuticals. "It will ultimately serve our customers, patients and doctors in Russia and thus strengthen our competitive position."
Bayer HealthCare and Medsintez will start their cooperation with the full cycle manufacturing of the antiinfectives Avelox™ and Ciprobay™, diagnostic imaging products, as well as Nimotop™ for treatment of neural disorders in existing as well as new facilities which will be built according to latest Good Manufacturing Practice (GMP) requirements.
"Medsintez and Bayer HealthCare will provide top quality products to the market, according to international standards", said Alexey Podkorytov, CEO of Medsintez. "In addition, the future research partnership with Bayer HealthCare will allow us to launch new drugs based on molecules developed by Russian research organizations to the international market."
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
Our online press service is just a click away: press.healthcare.bayer.com
Medsintez, located in the Sverdlovsk region of Russia, is a Russian company, with business interests in the fields of production of medical equipment and devices, as well as pharmaceuticals. Medsintez is the main enterprise of the Urals Pharmaceutical Cluster which includes more than 30 medical and pharmaceutical companies. Medsintez' key pharmaceutical products are Rosinsulin (human recombinant insulin), IV solutions and plastic containers for IV solutions. Medsintez has a number of additional medical devices and products under registration.
Find more information at www.bayerpharma.com.
Follow us on Facebook: http://www.facebook.com/healthcare.bayer
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.